Quality Control
Functionality tested in Real-time PCR for specificity, sensitivity and reproducibility for each primer sets using different cell lines, Breast cancer samples and Colon cancer tissues.
Radiotherapy Resistance Assay Service
NanoCinna Pharmacogenomics Center
Radiotherapy Resistance
Individualized cancer treatment has been an attractive concept since the beginning of cancer research. Despite advances in treatment, cancer remains the 2nd most common cause of death in many countries. Radiotherapy is a common treatment strategy used for the local control of many malignant disorders, including breast cancer, with 40% to 60% of all cancer patients receiving radiation treatment. In addition, radiotherapy is used with potentially curative intent for some early-stage cancers (e.g., laryngeal squamous cell carcinoma). The induction of DNA damage is probably one of the most crucial events after irradiation of cells. In this regard, ionizing radiation triggers a wide array of lesions including base damage, single-strand breaks, and, notably, double-strand breaks (DSB). Whereas most of the induced damage is quickly repaired, DSB repair is slow and unrepaired DSBs are important for the final induction of cell death. While the radiotherapy is efficient therapy, but in some patients a few tumor cells become resistant to radiation and go on to cause relapse and metastasis. Moreover, radiotherapy is associated with many unpleasant side effects. Also, multiple laboratories have shown that EGFR is rapidly activated in response to the irradiation of multiple tumor cell types in vitro (Willers and Held 2006; Bentzen et al. 2005; Astsaturov et al. 2006; Chinnaiyan et al. 2006; Kim et al. 2006; Kavanagh et al. 1995; Balaban et al. 1996). Low-dose, clinically relevant radiation exposure (~2 Gy) activates EGFR, and by heterodimerization, other members of the EGFR family (EGFR2, EGFR3, EGFR4); thus, although the irradiation of cells causes death, it also can enhance proliferation in the surviving fraction of cells and promote long-term resistance to multiple cytotoxic stresses.
NanoCinna introduces an experiment to expression analysis of 20 genes to find probability of resistance to radiotherapy.
Application
Evaluation of Radiotherapy sensitivity
Sampling Condition
Fresh or snap-frozen tumor and its tumor
borderline are needed, for more information
please contact us
Catalog Number
#S1376 Radiotherapy resistance assay
#S1376 description
NanoCinna evaluates the Radiotherapy resistante with expression analysis of 20 genes:
1- ATM 13- NFkB
2- BRCA1 14- VEGF
3- BAX 15- p21
4- BCL2 16- CCND1
5- BCLxL 17- EGR1
6- AIF 18- CHK1
7- CASP3 19- CHK2
8- CASP9 20- ERCC1
9- CASP7
10- BIRC5 (survivin)
11- TP53
12- ATR
